FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by th ...

Corporate and Financial Updates In April 2025, Invivyd secured a $30 million non-dilutive term loan facility with Silicon Valley Bank, a division of First Citizens Bank, supporting balance sheet ...

Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine ...

The pseudovirus assay is another humoral immunogenicity method that tests neutralising antibodies. Neutralisation assays measure the antibodies that exhibit in vitro neutralising activities using ...

Lilly said that pseudovirus and authentic virus testing demonstrate that bebtelovimab "retains full neutralising activity against Omicron," while pseudovirus testing shows it can neutralise other ...

such as pseudovirus assays and authentic assays; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitope that pemivibart and VYD2311 ...

WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended March 31, 2025, and provided recent business highlights.

This study presents an important finding on how lentiviral infection has driven the diversification of the HIV/SIV entry receptor CD4. Using a combination of molecular evolution approaches coupled ...